Literature DB >> 23287510

Regulation and role of connective tissue growth factor in AngII-induced myocardial fibrosis.

Nicole L Rosin1, Alec Falkenham, Mryanda J Sopel, Timothy D G Lee, Jean-Francois Légaré.   

Abstract

Exposure of rodents to angiotensin II (AngII) is a common model of fibrosis. We have previously shown that cellular infiltration of bone marrow-derived progenitor cells (fibrocytes) occurs before deposition of extracellular matrix and is associated with the production of connective tissue growth factor (CTGF). In the present study, we characterized the role of CTGF in promoting fibrocyte accumulation and regulation after AngII exposure. In animals exposed to AngII using osmotic minipumps (2.0 μg/kg per min), myocardial CTGF mRNA peaked at 6 hours (21-fold; P < 0.01), whereas transforming growth factor-β (TGF-β) peaked at 3 days (fivefold; P < 0.05) compared with saline control. Early CTGF expression occurred before fibrocyte migration (1 day) into the myocardium or ECM deposition (3 days). CTGF protein expression was evident by day 3 of AngII exposure and seemed to be localized to resident cells. Isolated cardiomyocytes and microvascular endothelial cells responded to AngII with increased CTGF production (2.1-fold and 2.8-fold, respectively; P < 0.05), which was abolished with the addition of anti-TGF-β neutralizing antibody. The effect of CTGF on isolated fibrocytes suggested a role in fibrocyte proliferation (twofold; P < 0.05) and collagen production (2.3-fold; P < 0.05). In summary, we provide strong evidence that AngII exposure first resulted in Smad2-dependent production of CTGF by resident cells (6 hours), well before the accumulation of fibrocytes or TGF-β mRNA up-regulation. In addition, CTGF contributes to fibrocyte proliferation in the myocardium and enhances fibrocyte differentiation into a myofibroblast phenotype responsible for ECM deposition.
Copyright © 2013 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23287510     DOI: 10.1016/j.ajpath.2012.11.014

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  21 in total

1.  Gq-activated fibroblasts induce cardiomyocyte action potential prolongation and automaticity in a three-dimensional microtissue environment.

Authors:  C M Kofron; T Y Kim; M E King; A Xie; F Feng; E Park; Z Qu; B-R Choi; U Mende
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-07-14       Impact factor: 4.733

2.  Protease-Activated Receptor 1 Contributes to Angiotensin II-Induced Cardiovascular Remodeling and Inflammation.

Authors:  Silvio Antoniak; Jessica C Cardenas; Laura J Buczek; Frank C Church; Nigel Mackman; Rafal Pawlinski
Journal:  Cardiology       Date:  2016-11-24       Impact factor: 1.869

Review 3.  Cardiac Fibrosis: The Fibroblast Awakens.

Authors:  Joshua G Travers; Fadia A Kamal; Jeffrey Robbins; Katherine E Yutzey; Burns C Blaxall
Journal:  Circ Res       Date:  2016-03-18       Impact factor: 17.367

4.  Fn14 is regulated via the RhoA pathway and mediates nuclear factor-kappaB activation by Angiotensin II.

Authors:  Zhengwei Li; Zhida Shen; Lailing Du; Jialin He; Shengyu Chen; Jiefang Zhang; Yi Luan; Guosheng Fu
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

5.  Inhibition of farnesyl pyrophosphate synthase prevents angiotensin II-induced cardiac fibrosis in vitro.

Authors:  Z Li; X Bi; M Wang; J Zhang; J Song; X Shen; J Han; G Fu; Y Ye
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

6.  ERK1/2 directly acts on CTGF/CCN2 expression to mediate myocardial fibrosis in cardiomyopathy caused by mutations in the lamin A/C gene.

Authors:  Maria Chatzifrangkeskou; Caroline Le Dour; Wei Wu; John P Morrow; Leroy C Joseph; Maud Beuvin; Fusako Sera; Shunichi Homma; Nicolas Vignier; Nathalie Mougenot; Gisèle Bonne; Kenneth E Lipson; Howard J Worman; Antoine Muchir
Journal:  Hum Mol Genet       Date:  2016-04-30       Impact factor: 6.150

7.  Time course of cardiac inflammation during nitric oxide synthase inhibition in SHR: impact of prior transient ACE inhibition.

Authors:  Lauren A Biwer; Karen M D'souza; Ali Abidali; Danni Tu; Ashley L Siniard; Matthew DeBoth; Matthew Huentelman; Taben M Hale
Journal:  Hypertens Res       Date:  2015-10-22       Impact factor: 3.872

8.  Prenatal exposure to lipopolysaccharide results in myocardial fibrosis in rat offspring.

Authors:  Xin Chen; Yujie Tang; Meng Gao; Shugang Qin; Jianzhi Zhou; Xiaohui Li
Journal:  Int J Mol Sci       Date:  2015-05-14       Impact factor: 5.923

9.  CXCL12 induces connective tissue growth factor expression in human lung fibroblasts through the Rac1/ERK, JNK, and AP-1 pathways.

Authors:  Chien-Huang Lin; Chung-Huang Shih; Chih-Chieh Tseng; Chung-Chi Yu; Yuan-Jhih Tsai; Mauo-Ying Bien; Bing-Chang Chen
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

10.  Antibody therapy can enhance AngiotensinII-induced myocardial fibrosis.

Authors:  Nicole L Rosin; Alison J Gareau; Devin Betsch; Alec Falkenham; Mryanda J Sopel; Timothy Dg Lee; Jean-Francois Légaré
Journal:  Fibrogenesis Tissue Repair       Date:  2014-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.